A controlled in vitro hypersensitivity assessment in subjects previously treated whit the combination of GLPG3067 and GLPG2222, or the combination of GLPG3067, GLPG222 and GLPG2737 using Lymphocyte Transformation Test. - Study to investigate hypersensitivity with a LTT test.

Galapagos N.V.0 个研究点目标入组 2 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•- trial subjects: subjects who participated in Part 4 or Part 5 of the GLPG3067 -CL -101 or the GLPG3067-CL-108 clinical trial and developed skin reactions suspected as drug hypersensitivity, OR
•-control subjects: subjects who participated in Part 4 or Part 5 of the GLPG3067- CL- 101 or the GLPG3067-CL-108 clinical trial and did not develop any skin reaction or drug hypersensitivity signs.;- Able and willing to comply with the protocol requirements and to sign the ICF as approved by the Independent Ethics Committee (IEC), before any study-related procedures are performed.

•- Any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.

发起方

Galapagos N.V.